{"id":"eperisone","rwe":[{"pmid":"41850224","year":"2026","title":"Drug hypersensitivity leading to emergency department visit: a comprehensive analysis of clinical features and management.","finding":"","journal":"The Korean journal of internal medicine","studyType":"Clinical Study"},{"pmid":"41063709","year":"2026","title":"Effectiveness of glucosamine hydrochloride and eperisone with exercise therapy on inflammatory factors and knee joint function in patients with knee osteoarthritis.","finding":"","journal":"Journal of drug targeting","studyType":"Clinical Study"},{"pmid":"41051811","year":"2025","title":"[The effectiveness of using a centrally acting muscle relaxant in combination with botulinum toxin injections in patients with spasmodic torticollis].","finding":"","journal":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","studyType":"Clinical Study"},{"pmid":"39967634","year":"2025","title":"Eperisone Analogs, Rescuers of MiaB Defects As a Prokaryotic Homologue of CDKAL1, Suppress Blood Glucose Elevation in Rats.","finding":"","journal":"ACS medicinal chemistry letters","studyType":"Clinical Study"},{"pmid":"39482828","year":"2024","title":"Ultrasound-Guided Fascial Hydrodissection with Eperisone: A Retrospective Study on Efficacy and Safety in Lumbodorsal Fasciitis Treatment.","finding":"","journal":"Medical science monitor : international medical journal of experimental and clinical research","studyType":"Clinical Study"}],"tags":[{"label":"eperisone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sigma non-opioid intracellular receptor 1","category":"target"},{"label":"SIGMAR1","category":"gene"},{"label":"CHRM2","category":"gene"},{"label":"ADRA2B","category":"gene"},{"label":"M03BX09","category":"atc"},{"label":"Active","category":"status"},{"label":"Spasm","category":"indication"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Muscle Relaxants, Central","category":"pharmacology"},{"label":"Neuromuscular Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":44.067,"date":"","count":22,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=44)"},{"llr":39.6,"date":"","count":26,"signal":"Hypokalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=40)"},{"llr":32.497,"date":"","count":12,"signal":"Spinal compression fracture","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=32)"},{"llr":29.489,"date":"","count":23,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=29)"},{"llr":26.441,"date":"","count":7,"signal":"Renal tubular acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=26)"}],"commonSideEffects":[{"effect":"Hepatic function abnormal","drugRate":"LLR 44","severity":"common"},{"effect":"Hypokalaemia","drugRate":"LLR 40","severity":"common"},{"effect":"Spinal compression fracture","drugRate":"LLR 32","severity":"common"},{"effect":"Renal impairment","drugRate":"LLR 29","severity":"common"},{"effect":"Renal tubular acidosis","drugRate":"LLR 26","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"(+/-)-eperisone","offLabel":[],"synonyms":["eperisone","(+/-)-Eperisone","eperisone hydrochloride","eperisone HCl"],"timeline":[],"approvals":[],"brandName":"(+/-)-Eperisone","ecosystem":[{"indication":"Spasm","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Sigma non-opioid intracellular receptor 1","targets":[{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"}],"modality":"Small Molecule","drugClass":"eperisone","explanation":"Imagine your muscles are like a bunch of excited kids in a playground. When they get overexcited, they start to spasm and get stiff. Eperisone helps calm them down by binding to a specific receptor that tells the muscles to relax.","oneSentence":"Eperisone works by binding to the Sigma non-opioid intracellular receptor 1, which helps to reduce muscle spasms.","technicalDetail":"Eperisone acts as a selective agonist of the Sigma-1 receptor, a type of intracellular receptor that plays a role in regulating muscle contraction and relaxation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1022","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPERISONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPERISONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:57:38.950825","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:38:18.254263+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"baclofen","drugSlug":"baclofen","fdaApproval":"1977-11-22","patentExpiry":"Sep 8, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tizanidine","drugSlug":"tizanidine","fdaApproval":"1996-11-27","patentExpiry":"May 7, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cyclobenzaprine","drugSlug":"cyclobenzaprine","fdaApproval":"1977-08-26","patentExpiry":"Mar 14, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"eperisone","indications":{"approved":[{"name":"Spasm","source":"DrugCentral","snomedId":45352006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"baclofen","brandName":"baclofen","genericName":"baclofen","approvalYear":"1977","relationship":"same-class"},{"drugId":"tizanidine","brandName":"tizanidine","genericName":"tizanidine","approvalYear":"1996","relationship":"same-class"},{"drugId":"cyclobenzaprine","brandName":"cyclobenzaprine","genericName":"cyclobenzaprine","approvalYear":"1977","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03337607","phase":"NA","title":"Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2017-11-13","conditions":["Low Back Pain"],"enrollment":150,"completionDate":"2019-08-01"},{"nctId":"NCT06415331","phase":"NA","title":"Effectiveness of Conventional Therapy Plus Pulsed-Radiofrequency for Herniated Nucleus Pulposus","status":"COMPLETED","sponsor":"Dr. Syaiful Anwar Hospital, Malang","startDate":"2023-02-02","conditions":["Herniated Nucleus Pulposus","Pain"],"enrollment":60,"completionDate":"2023-09-16"},{"nctId":"NCT02289274","phase":"PHASE1","title":"Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203","status":"WITHDRAWN","sponsor":"NVP Healthcare","startDate":"2019-11","conditions":["Healthy"],"enrollment":0,"completionDate":"2019-12"},{"nctId":"NCT03424707","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2016-03-04","conditions":["Acute Low Back Pain"],"enrollment":45,"completionDate":"2016-08-30"},{"nctId":"NCT02040415","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2014-03","conditions":["Acute Back Pain"],"enrollment":242,"completionDate":""},{"nctId":"NCT01885520","phase":"PHASE1","title":"Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Eperisone HCl SR Tablet 75mg","status":"COMPLETED","sponsor":"NVP Healthcare","startDate":"2013-07","conditions":["Low Back Pain"],"enrollment":28,"completionDate":"2013-07"},{"nctId":"NCT01306318","phase":"NA","title":"A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-02","conditions":["Healthy Volunteers"],"enrollment":24,"completionDate":"2011-02"},{"nctId":"NCT00327730","phase":"PHASE3","title":"Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-04","conditions":["Muscle Spasm; Back Pain"],"enrollment":240,"completionDate":"2006-06"},{"nctId":"NCT01638286","phase":"","title":"Study to Evaluate a Pharmacokinetic Drug Interaction Between Eperisone Hydrochloride and Aceclofenac in Healthy Male Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-08","conditions":["Acute Low Back Pain"],"enrollment":24,"completionDate":"2013-04"},{"nctId":"NCT01869985","phase":"PHASE1","title":"Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2013-08","conditions":["Healthy"],"enrollment":30,"completionDate":"2014-01"},{"nctId":"NCT01775566","phase":"","title":"Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mg","status":"COMPLETED","sponsor":"NVP Healthcare","startDate":"2013-03","conditions":["Low Back Pain"],"enrollment":27,"completionDate":"2013-06"},{"nctId":"NCT01806818","phase":"PHASE2","title":"Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2013-02","conditions":["Low Back Pain"],"enrollment":98,"completionDate":"2013-07"},{"nctId":"NCT01300312","phase":"PHASE3","title":"A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-02","conditions":["Acute Musculoskeletal Spasm Due to Low Back Pain"],"enrollment":239,"completionDate":"2011-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010914","UNII":"2M2P0551D3","CHEBI":"CHEBI:77069","INN_ID":"5153","UMLSCUI":"C0043606","ChEMBL_ID":"CHEMBL1902981","KEGG_DRUG":"D01671","DRUGBANK_ID":"DB08992","PUBCHEM_CID":"3236","SECONDARY_CAS_RN":"56839-43-1","MESH_SUPPLEMENTAL_RECORD_UI":"C030848"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":117,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"M03BX09","allCodes":["M03BX09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar","pmid":"41850224","title":"Drug hypersensitivity leading to emergency department visit: a comprehensive analysis of clinical features and management.","journal":"The Korean journal of internal medicine"},{"date":"2026 Apr","pmid":"41063709","title":"Effectiveness of glucosamine hydrochloride and eperisone with exercise therapy on inflammatory factors and knee joint function in patients with knee osteoarthritis.","journal":"Journal of drug targeting"},{"date":"2025","pmid":"41051811","title":"[The effectiveness of using a centrally acting muscle relaxant in combination with botulinum toxin injections in patients with spasmodic torticollis].","journal":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova"},{"date":"2025 Feb 13","pmid":"39967634","title":"Eperisone Analogs, Rescuers of MiaB Defects As a Prokaryotic Homologue of CDKAL1, Suppress Blood Glucose Elevation in Rats.","journal":"ACS medicinal chemistry letters"},{"date":"2024 Nov 1","pmid":"39482828","title":"Ultrasound-Guided Fascial Hydrodissection with Eperisone: A Retrospective Study on Efficacy and Safety in Lumbodorsal Fasciitis Treatment.","journal":"Medical science monitor : international medical journal of experimental and clinical research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:38:18.254263+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}